Not yet recruitingPriority 4 · Lower priorityNCT07477769

Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)

Plain-language summary

This study is studying blood sampling for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

Age 18 Years or older
See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

blood sampling (OTHER): Supplementary blood collection performed during routine venipuncture

Drugs / treatments: blood sampling
Treatment length: Ask the trial team for details
Visit frequency: Ask the trial team for details

TrialCompass — Clinical Trial Summary

Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)

NCT07477769

Status: Not yet recruiting | Priority: Lower

Plain-language summary

Who can join

Age 18 Years or older
See full trial listing for complete eligibility

What's being tested

blood sampling (OTHER): Supplementary blood collection performed during routine venipuncture

Drugs / treatments: blood sampling

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 10 patients

Primary endpoint: Proportion of blood lymphocyte phenotype

Ages: 18 Years to —

Start date: 2026-04-01 | Est. completion: 2027-10-01

Locations

0 US sites · 0 total

Contact

Emmanuelle Bourrat, MD | emmanuelle.bourrat@aphp.fr | 01 42 49 90 90

Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07477769

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.